Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. 1038915-73-9
2. Mk-4827 Tosylate
3. Mk-4827 (tosylate)
4. Mk-4827-tosylate
5. Niraparib (tosylate)
6. Mk 4827 Tosylate
7. Niraparib (mk-4827) Tosylate
8. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-methylbenzenesulfonate
9. 75ke12ay9u
10. Mk-4827(niraparib) Tosylate
11. 2h-indazole-7-carboxamide, 2-(4-(3s)-3-piperidinylphenyl)-, 4-methylbenzenesulfonate (1:1)
12. Unii-75ke12ay9u
13. Niraparib Tosylate Monohyrate
14. Niraparib(mk-4827) Tosylate
15. Schembl20522624
16. Dtxsid801026487
17. Hy-10619b
18. Mfcd28167748
19. S7625
20. Ccg-269634
21. Niraparib Tosylate [orange Book]
22. Ac-30383
23. As-56981
24. A11848
25. A909268
26. Q27266392
27. (3s)-3-[4-[7-(aminocarbonyl)-2h-indazol-2-yl]phenyl]piperidine Tosylate
28. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-?methylbenzenesulfona?te
29. 4-methylbenzenesulfonic Acid;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide
30. 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 4-methylbenzene-1-sulfonic Acid
Molecular Weight | 492.6 g/mol |
---|---|
Molecular Formula | C26H28N4O4S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 492.18312656 g/mol |
Monoisotopic Mass | 492.18312656 g/mol |
Topological Polar Surface Area | 136 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 655 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Niraparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Niraparib, including repackagers and relabelers. The FDA regulates Niraparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Niraparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Niraparib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Niraparib supplier is an individual or a company that provides Niraparib active pharmaceutical ingredient (API) or Niraparib finished formulations upon request. The Niraparib suppliers may include Niraparib API manufacturers, exporters, distributors and traders.
click here to find a list of Niraparib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Niraparib written confirmation (Niraparib WC) is an official document issued by a regulatory agency to a Niraparib manufacturer, verifying that the manufacturing facility of a Niraparib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Niraparib APIs or Niraparib finished pharmaceutical products to another nation, regulatory agencies frequently require a Niraparib WC (written confirmation) as part of the regulatory process.
click here to find a list of Niraparib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Niraparib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Niraparib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Niraparib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Niraparib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Niraparib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Niraparib suppliers with NDC on PharmaCompass.
Niraparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Niraparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Niraparib GMP manufacturer or Niraparib GMP API supplier for your needs.
A Niraparib CoA (Certificate of Analysis) is a formal document that attests to Niraparib's compliance with Niraparib specifications and serves as a tool for batch-level quality control.
Niraparib CoA mostly includes findings from lab analyses of a specific batch. For each Niraparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Niraparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Niraparib EP), Niraparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Niraparib USP).
LOOKING FOR A SUPPLIER?